Sana Biotechnology (NASDAQ:SANA) Cut to “Sell” at Wall Street Zen

Wall Street Zen downgraded shares of Sana Biotechnology (NASDAQ:SANA) from a hold rating to a sell rating in a research report report published on Saturday.

Other equities analysts also recently issued reports about the company. JMP Securities set a $8.00 price objective on shares of Sana Biotechnology in a research note on Thursday, October 30th. Citigroup reiterated an “outperform” rating on shares of Sana Biotechnology in a research report on Thursday, October 30th. Wedbush raised their price objective on shares of Sana Biotechnology from $5.00 to $6.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th. Citizens Jmp upped their target price on Sana Biotechnology from $5.00 to $8.00 and gave the company a “market outperform” rating in a research note on Thursday, October 30th. Finally, Zacks Research upgraded Sana Biotechnology from a “hold” rating to a “strong-buy” rating in a report on Friday, January 23rd. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $8.14.

Sana Biotechnology Stock Up 1.8%

NASDAQ:SANA opened at $4.00 on Friday. The company has a market capitalization of $1.07 billion, a PE ratio of -4.12 and a beta of 1.96. The stock’s 50 day moving average price is $4.54 and its 200 day moving average price is $4.12. Sana Biotechnology has a 52-week low of $1.26 and a 52-week high of $6.55.

Institutional Trading of Sana Biotechnology

A number of hedge funds have recently made changes to their positions in the company. AQR Capital Management LLC raised its holdings in Sana Biotechnology by 49.8% in the first quarter. AQR Capital Management LLC now owns 573,146 shares of the company’s stock valued at $963,000 after acquiring an additional 190,483 shares in the last quarter. Woodline Partners LP raised its stake in shares of Sana Biotechnology by 13.1% in the 1st quarter. Woodline Partners LP now owns 780,656 shares of the company’s stock valued at $1,312,000 after purchasing an additional 90,515 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its stake in shares of Sana Biotechnology by 68.0% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 50,849 shares of the company’s stock valued at $139,000 after purchasing an additional 20,585 shares in the last quarter. CWM LLC lifted its position in shares of Sana Biotechnology by 125.7% during the second quarter. CWM LLC now owns 86,750 shares of the company’s stock worth $237,000 after purchasing an additional 48,319 shares during the last quarter. Finally, WealthPlan Investment Management LLC acquired a new position in Sana Biotechnology in the second quarter worth about $48,000. Hedge funds and other institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.